Specific and Sensitive Diagnosis of BCOR -ITD in Various Cancers by Digital PCR

• Published in: Frontiers in oncology 2021-02, Vol.11, p.645512-645512
• Main Authors: Barets, Doriane, Appay, Romain, Heinisch, Marie, Battistella, Maxime, Bouvier, Corinne, Chotard, Guillaume, Le Loarer, François, Macagno, Nicolas, Perbet, Romain, Pissaloux, Daniel, Rousseau, Audrey, Tauziède-Espariat, Arnaud, Varlet, Pascale, Vasiljevic, Alexandre, Colin, Carole, Fina, Frédéric, Figarella-Branger, Dominique
• Format: Article
• Language: English
• Subjects: BCOR-internal tandem duplication; Biochemistry, Molecular Biology; Cancer; diagnostic marker; digital PCR assay; FFPE tissue; Genetics; HGNET-BCOR; Human health and pathology; Life Sciences; Oncology
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.645512

is an epigenetic regulator altered by various mechanisms including -internal tandem duplication ( -ITD) in a wide range of cancers. Six different -ITD in the 3'-part of the coding sequence of exon 15 have been reported ranging from 89 to 114 bp in length. -ITD is a common genetic alteration found in clear cell sarcoma of the kidney and primitive myxoid mesenchymal tumor of infancy (PMMTI) and it characterizes a new type of central nervous system tumor: "CNS tumor with -ITD". It can also be detected in undifferentiated round cell sarcoma (URCS) and in high-grade endometrial stromal sarcoma (HGESS). Therefore, it is of utmost importance to search for this genetic alteration in these cancers with the most frequent technique being RNA-sequencing. Here, we developed a new droplet PCR assay (dPCR) to detect the six sequences characterizing -ITD. To achieve this goal, we used a single colored probe to detect both the duplicated region and the normal sequence that acts as a reference. We first generated seven synthetic DNA sequences: ITD0 (the normal sequence) and ITD1 to ITD6 (the duplicated sequences described in the literature) and then we set up the optima dPCR conditions. We validated our assay on 19 samples from a representative panel of human tumors (9 HGNET-BCOR, 5 URCS, 3 HGESS, and 2 PMMTI) in which -ITD status was known using at least one other method including RNA sequencing, RT-PCR or DNA-methylation profiling for CNS tumors. Our results showed that our technique was 100% sensitive and specific. DPCR detected -ITD in 13/19 of the cases; in the remaining 6 cases additional RNA-sequencing revealed gene fusions. To conclude, in the era of histomolecular classification of human tumors, our modified dPCR assay is of particular interest to detect -ITD since it is a robust and less expensive test that can be applied to a broad spectrum of cancers that share this alteration.